Psyence Biomedical (PBM) Debt Ratio (2023 - 2024)
Psyence Biomedical (PBM) posted Debt Ratio of 0.56 for Q3 2024, down 39.77% on a QoQ basis from 0.92 in Q1 2024, and up 252.52% year-over-year from 0.16 in Q4 2023.
Powered by 
Analysis
Psyence Biomedical (PBM) Debt Ratio (2023 - 2024) Analysis & Trends
Psyence Biomedical has reported Debt Ratio for 2 years, with the latest figure at 0.56 in Q3 2024.
- On a quarterly basis, Debt Ratio rose 252.52% year-over-year to 0.56 in Q3 2024; TTM through Sep 2024 was 0.56, a 252.52% increase from a year earlier, with the FY2024 full-year figure at 1.3, changed N/A from the prior year.
- Debt Ratio was 0.56 for Q3 2024 at Psyence Biomedical, down from 0.92 in the prior quarter.
- The five-year high for Debt Ratio was 0.92 in Q1 2024, with the low at 0.16 in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.86 Bn | 192.87 Bn | 7.24 Bn | 0.66 |
| 2 | Gilead Sciences | 179.52 Bn | 176.34 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 131.47 Bn | 123.62 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 0.05 |
| 5 | Argenx Se | 61.16 Bn | 55.98 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.15 Bn | 48.02 Bn | 52.00 Mn | 0.05 |
| 7 | Alnylam Pharmaceuticals | 33.20 Bn | 29.89 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.65 Bn | 30.37 Bn | 1.96 Bn | 0.25 |
| 9 | Roivant Sciences | 29.30 Bn | 29.30 Bn | 1.16 Mn | - |
| 10 | Psyence Biomedical | 2.63 Mn | 2.63 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 0.56 |
| Mar 31, 2024 | 0.92 |
| Sep 30, 2023 | 0.16 |